Enablex Disease Interactions

Darifenacin is contraindicated in patients with gastric retention. Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.

Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma. It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.

Darifenacin is contraindicated in patients with urinary retention. Darifenacin is a competitive muscarinic receptor antagonist. It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.

Darifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased. It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects. Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.

Darifenacin is extensively metabolized by the liver following oral dosing. The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B). Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).